CCS
EXEL icon

Crosspoint Capital Strategies’s Exelixis EXEL Stock Holding History

Crosspoint Capital Strategies’s Portfolio EXEL Stock Details EXEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-209
Closed -$5K – 133
2017
Q2 		$5K Sell
209
-163,908
-100% -$3.47M ﹤0.01% 109
2017
Q1 		$3.56M Buy
+164,117
New +$3.34M 2.98% 19

Other funds holding EXEL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Crosspoint Capital Strategies's EXEL Position: Q3 2017 in Review

Crosspoint Capital Strategies sold out of Exelixis (EXEL) in Q3 2017, closing a stake of 209 shares — an estimated $5K sold.

Crosspoint Capital Strategies first reported a position in EXEL in Q1 2017 and held it in 2 quarters. The position peaked at $3.56M in Q1 2017. 264 funds tracked by Wall St. Rank hold EXEL as of Q3 2017.

  • Crosspoint Capital Strategies reported no remaining Exelixis position as of Q3 2017 after selling out during the quarter.
  • Crosspoint Capital Strategies sold 209 Exelixis shares in Q3 2017, an estimated $5K.
  • Crosspoint Capital Strategies first reported a position in Exelixis in Q1 2017 and held it in 2 quarters.
  • Crosspoint Capital Strategies's Exelixis position peaked at $3.56M in Q1 2017.
  • 264 funds tracked by Wall St. Rank held Exelixis as of Q3 2017.

Based on Crosspoint Capital Strategies's 13F filing for Q3 2017, filed 6 Nov 2017.